10q10k10q10k.net
Autolus Therapeutics plc

Autolus Therapeutics plcAUTLEarnings & Financial Report

Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company specializing in the development of next-generation engineered chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of hematological malignancies and solid tumors. It operates in the global oncology biotech market, advancing a pipeline of targeted immunotherapy candidates across multiple clinical development stages.

Q3 2025Q2 2025Q1 2025Q3 2024Q2 2024Q1 2024

Revenue

$9.0M

Gross Profit

$-9.0M

Operating Profit

$-65.2M

Net Profit

$-70.2M

Gross Margin

-99.9%

Operating Margin

-726.3%

Net Margin

-781.1%

YoY Growth

-11.0%

EPS

$-0.26

Autolus Therapeutics plc Q1 FY2025 Financial Summary

Autolus Therapeutics plc reported revenue of $9.0M (down 11.0% YoY) for Q1 FY2025, with a net profit of $-70.2M (down 33.2% YoY) (-781.1% margin).

Key Financial Metrics

Total Revenue$9.0M
Net Profit$-70.2M
Gross MarginN/A
Operating Margin-726.3%
Report PeriodQ1 FY2025

Autolus Therapeutics plc Quarterly Revenue & Net Profit History

Autolus Therapeutics plc results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q3 FY2025$21.2M—$-79.1M-373.3%
Q2 FY2025$20.9M—$-47.9M-229.0%
Q1 FY2025$9.0M-11.0%$-70.2M-781.1%
Q3 FY2024$0—$-82.1MN/A
Q2 FY2024$0—$-58.3MN/A
Q1 FY2024$10.1M—$-52.7M-522.1%

Income Statement

Q1 2024Q2 2024Q3 2024Q1 2025Q2 2025Q3 2025
Revenue$10.1M$0$0$9.0M$20.9M$21.2M
YoY GrowthN/AN/AN/A-11.0%N/AN/A

Balance Sheet

Q1 2024Q2 2024Q3 2024Q1 2025Q2 2025Q3 2025
Assets$901.4M$853.6M$827.5M$746.3M$721.0M$661.9M
Liabilities$319.4M$325.8M$350.5M$375.2M$374.5M$396.5M
Equity$582.0M$527.8M$477.0M$371.1M$346.5M$265.5M

Cash Flow

Q1 2024Q2 2024Q3 2024Q1 2025Q2 2025Q3 2025
Operating CF$-40.5M$-51.1M$-76.7M$-75.6M$-72.8M$-67.9M